How does methotrexate suppress inflammation?

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 61, 2010, Pages

  Cronstein, B ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenosine; Inflammation; Methotrexate; Purine metabolism

Indexed keywords

ADENOSINE; ADENOSINE PHOSPHATE; DIHYDROFOLATE REDUCTASE; FOLIC ACID; HOMOCYSTEINE; METHIONINE; METHOTREXATE; METHOTREXATE POLYGLUTAMATE; PEROXIDE; REACTIVE OXYGEN METABOLITE; TETRAHYDROFOLIC ACID; ADENOSINE A2A RECEPTOR; FOLINIC ACID;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CELL PROLIFERATION; DRUG MECHANISM; INFLAMMATION; METHYLATION; PRIORITY JOURNAL; PURINE METABOLISM; PYRIMIDINE METABOLISM; ALOPECIA; ANEMIA; ANTIPROLIFERATIVE ACTIVITY; CASE CONTROL STUDY; DIGESTIVE SYSTEM ULCER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKOPENIA; LIVER FIBROSIS; LIVER TOXICITY; META ANALYSIS (TOPIC); NONHUMAN; PATHOGENESIS; PHARMACOGENETICS; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SOMNOLENCE; STOMATITIS;

ADENOSINE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INFLAMMATION MEDIATORS; METHOTREXATE; TREATMENT OUTCOME;

EID: 78650528837     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. GUBNER R, AUGUST S, GINSBERG V: Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951;221:176-82.
2. VISSER K, KATCHAMART W, LOZA E et al.: Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086-93.
3. MATHERLY LH, GOLDMAN DI: Membrane transport of folates. Vitam Horm 2003;66:403-56.
4. JANSEN G, VAN DER HEUDEN J, OERLEMANS R et al.: Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum 2004;50:2130-9.
5. PHILLIPS DC, WOOLLARD KJ, GRIFFITHS HR: The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br J Pharmacol 2003;138:501-11.
6. NESHER G, MOORE TL, DORNER RW: In vitro effects of methotrexate on peripheral blood monocytes: modulation by folinic acid and S-adenosylmethionine. Ann Rheum Dis 1991;50:637-41.
7. NESHER G, MOORE TM: The in vitro effects of methotrexate on peripheral blood mononuclear cells: modulation by methyl donors and spermidine. Arthritis Rheum 1990;33:954-9.
8. NESHER G, OSBORN TG, MOORE TL: In vitro effects of methotrexate on polyamine levels in lymphocytes from rheumatoid arthritis patients. Clin Exp Rheumatol 1996;14:395-9.
9. SMITH DM, JOHNSON JA, TURNER RA: Biochemical perturbations of BW 91Y (3-deazaadenosine) on human neutrophil chemotactic potential and lipid metabolism. Int J Tissue React 1991;13:1-18.
10. RIKSEN NP, BARRERA P, VAN DEN BROEK PH et al.: Methotrexate modulates the kinetics of adenosine in humans in vivo. Ann Rheum Dis 2006;65:465-70.
11. RIKSEN NP, RONGEN GA, YELLON D, SMITS P: Human in vivo research on the vascular effects of adenosine. Eur J Pharmacol 2008;585:220-7.
12. CRONSTEIN BN, EBERLE MA, GRUBER HE, LEVIN RI: Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Nat Acad Sci USA 1991;88:2441-5.
13. CRONSTEIN BN, NAIME D, OSTAD E: The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675-82.
14. BAGGOTT JE, MORGAN SL, VAUGHN WH: Differences in methotrexate and 7-hydroxymethotrexate inhibition of folate-dependent enzymes of purine nucleotide biosynthesis. Biochem J 1994;300(Pt 3):627-9.
15. MONTESINOS MC, TAKEDACHI M, THOMPSON LF et al.: The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5'-nucleotidase: Findings in a study of ecto-5'-nucleotidase gene-deficient mice. Arthritis Rheum 2007;56:1440-5.
16. MONTESINOS C, YAP JS, DESAI A et al.: Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine. Evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum 2000;43:656-63.
17. MONTESINOS MC, DESAI A, CRONSTEIN BN: Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis. Arthritis Res Ther 2006;8: R53.
18. MONTESINOS MC, DESAI A, DELANO D et al.: Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003;48:240-7.
19. MORABITO L, MONTESINOS MC, SCHREIBMAN DM et al.: Methotrexate and Sulfasalazine Promote Adenosine Release by a Mechanism that Requires Ecto-5'-nucleotidase-mediated Conversion of Adenine Nucleotides. J Clin Invest 1998;101:295-300.
20. DELANO DL, MONTESINOS MC, DESAI A et al.: Genetically based resistance to the antiinflammatory effects of methotrexate in the air-pouch model of acute inflammation. Arthritis Rheum 2005;52:2567-75.
21. SILKE C, MURPHY MS, BUCKLEY T et al.: The effects of caffeine ingestion on the efficacy of methotrexate. Rheumatology (Oxford) 2001;40(Suppl. 1):34.
22. NESHER G, MATES M, ZEVIN S: Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum 2003;48:571-2.
23. BENITO-GARCIA E, HELLER JE, CHIBNIK LB et al.: Dietary caffeine intake does not affect methotrexate efficacy in patients with rheumatoid arthritis. J Rheumatol 2006;33:1275-1281.
24. DERVIEUX T, WESSELS JA, VAN DER STRAATEN T et al.: Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. Pharmacogenet Genomics 2009 Oct. 24. [Epub ahead of prim]
25. WESSELS JA, DE VRIES-BOUWSTRA JK, HEIJMANS BT et al.: Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 2006;54:1087-95.
26. WESSELS JA, KOOLOOS WM, JONGE RD et al.: Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2006;54:28309.
27. DERVIEUX T: Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false-positive report probability. Rheumatology (Oxford) 2009;48:597-8.
28. DERVIEUX T, BALA MV: Overview of the pharmacoeconomics of pharmacogenetics. Pharmacogenomics 2006;7:1175-84.
29. DERVIEUX T, FURST D, LEIN DO et al.: Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis 2005;64:1180-5.
30. DERVIEUX T, FURST D, LEIN DO et al.: Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004;50:2766-74.
31. DERVIEUX T, GREENSTEIN N, KREMER J: Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 2006;54:3095-103.
32. WEISMAN MH, FURST DE, PARK GS et al.: Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum 2006;54:607-12.
33. PENG Z, BOREA PA, WILDER T et al.: Adenosine signaling contributes to ethanol-induced fatty liver in mice. J Clin Invest 2009;119:582-94.
34. ABLIN JN, BOGUSLAVSKI V, ALOUSH V et al.: Effect of anti-TNFalpha treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci 2006;79:2364-9.
35. PENG Z, FERNANDEZ P, WILDER T et al.: Ecto-5'-nucleotidase (CD73)-mediated extracellular adenosine production plays a critical role in hepatic fibrosis. Faseb J 2008;22:2263-72. (Pubitemid 351948645)
36. HAYAISHI O: Molecular genetic studies on sleep-wake regulation, with special emphasis on the prostaglandin D (2) system. J Appl Physiol 2002;92:863-868.
37. IKEDA M, SAGARA M, SEKINO Y et al.: The sulphydryl reagent, N-ethylmaleimide, disrupts sleep and blocks A1 adenosine receptormediated inhibition of intracellular calcium signaling in the in vivo ventromedial preoptic nucleus. Neuroscience 2001;106:733-43.
38. MURILLO-RODRIGUEZ E, BLANCO-CENTURION C, GERASHCHENKO D, SALIN-PASCUAL RJ, SHIROMANI PJ: The diurnal rhythm of adenosine levels in the basal forebrain of young and old rats. Neuroscience 2004;123:361-70.
39. STENBERG D: Neuroanatomy and neurochemistry of sleep. Cell Mol Life Sci 2007;64:1187-204.
40. STENBERG D, LITONIUS E, HALLDNER L et al.: Sleep and its homeostatic regulation in mice lacking the adenosine A1 receptor. J Sleep Res 2003;12:283-90.
41. THAKKAR MM, ENGEMANN SC, WALSH KM, SAHOTA PK: Adenosine and the homeostatic control of sleep: effects of A1 receptor blockade in the perifornical lateral hypothalamus on sleep-wakefulness. Neuroscience 2008;153:875-80.
42. BERNINI JC, FORT DW, GRIENER JC et al.: Aminophylline for methotrexate-induced neurotoxicity. Lancet 1995;345:544-7.
43. HASKO G, CRONSTEIN BN: Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004;25:33-9.
44. HASKO G, LINDEN J, CRONSTEIN B, PACHER P: Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008;7:759-70.